Tag: IHL

Incannex Healthcare ASX IHL United States Securities and Exchange Commission initial public offering IPO Nasdaq medicinal cannabis

Incannex Healthcare proposes US IPO and Nasdaq listing

Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has filed a registration statement with the United States Securities and Exchange Commission (SEC) relating to a propos...
Incannex Healthcare ASX IHL phase two psychedelics study treat generalised anxiety disorder psilocybin

Incannex Healthcare submits proposals for phase two psychedelics study to treat generalised anxiety disorder

Clinical-stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a Human Research Ethics Committee submission for a phase 2a Psi-GAD study, which combines the administrat...
Incannex Healthcare ASX IHL CMAX Clinical Research South Australia managed Avance Clinical soft gel

Incannex Healthcare begins clinical trial using IHL-675A soft gel capsules

Clinical stage cannabinoid and psychedelic medicine development company Incannex Healthcare (ASX: IHL) has started a phase 1 clinical trial assessing a soft gel capsule formulation of its multi-use dr...
Incannex Healthcare ASX IHL files patent application IHL-42X ethics approval open label extension obstructive sleep apnoea OSA

Incannex files patent application for IHL-42X and receives ethics approval for open label extension

Clinical stage cannabinoid and psychedelic development company Incannex Healthcare (ASX: IHL) has filed an international patent application as part of the development program for its drug IHL-42X for ...
Incannex Healthcare ASX IHL Unigel capsule technology formulations lead drug IHL-675A

Incannex Healthcare appoints Procaps to develop capsule formulations for drug IHL-675A

Specialised pharmaceutical manufacturer Procaps SA has been engaged by Incannex Healthcare (ASX: IHL) to develop the specific formulation for its drug IHL-675A using Procaps’ Unigel capsule technology...
Incannex Healthcare ASX IHL Vectura traumatic brain injury tbi product registration

Incannex Healthcare to develop IHL-216A formulation for traumatic brain injury clinical trials

Cannabinoid development company Incannex Healthcare (ASX: IHL) has announced it has engaged drug manufacturer Vectura Limited to develop the specific formulation required for clinical trials of IHL-21...
Incannex Healthcare ASX IHL University of WA obstructive sleep apnoea trial

Incannex partners with University of WA as additional site for ongoing phase 2b sleep apnoea trial

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has engaged the University of Western Australia’s Centre for Sleep Science as an additional site for an ongoing trial i...
CBD PBS medicinal cannabis Australia subsidy ASX IHL Dravet syndrome epilepsy

First subsidised CBD oil shows promise for Incannex Healthcare’s own medical cannabis drugs in Australia

In a historic first, a medicinal cannabis drug has been listed on Australia’s Pharmaceutical Benefits Scheme (PBS), enabling Australians living with Dravet syndrome access to treatment for the rare fo...
Incannex Healthcare ASX IHL IND lung inflammation irritable bowel syndrome rheumatoid arthritis

Incannex Healthcare plans US regulatory pathway for IHL-675A in treating multiple inflammatory conditions

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has held a pre-investigational new drug application meeting with the US Food and Drug Administration (US FDA) to discus...
Hallucinogens ASX depression post traumatic stress disorder PTSD psychedelic psychotherapy

With their mind-blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?

The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medi...
Incannex Healthcare ASX IHL sepsis associated acute respiratory distress syndrome SAARDS ARDS

Incannex Healthcare secures pre-IND meeting with US FDA to progress IHL-675A in treating SAARDS and ARDS

Incannex Healthcare (ASX: IHL) will confer with the United States Food and Drug Administration after the body granted a pre-investigational new drug meeting regarding progressing the company’s IHL-675...
Incannex Healthcare rheumatoid arthritis study results ASX IHL

Incannex Healthcare study results point to IHL-675A as a treatment option for rheumatoid arthritis

Positive results from an in vivo study model using Incannex Healthcare’s (ASX: IHL) lead candidate IHL-675A have triggered the launch of a sixth clinical program investigating the benefits of the drug...
Incannex Healthcare ASX IHL Monash University Trauma Group NFL sport concussion

Incannex Healthcare and Monash Trauma Group to undertake sports concussion study using model developed by the NFL

Incannex Healthcare (ASX: IHL) has revealed it will work with Monash Trauma Group on an “extensive” in vivo study evaluating the protective effect of IHL-216A in sports concussion. Monash Trauma Gr...
Incannex Healthcare Inflammatory Bowel Disease ASX IHL cannabis cannabidiol hydroxychloroquine

Incannex Healthcare’s drug candidate IHL-675A could become a multi-use medication

Incannex Healthcare (ASX: IHL) has been buoyed by the potential of its candidate IHL-675A to become a multi-use medication after receiving positive results from another pre-clinical in vivo trial into...
Incannex Healthcare ASX IHL Austrian clinic CBD oil COVID-19 Klagenfurt Clinic

Incannex Healthcare attracts interest as Austrian clinic uses CBD to treat COVID-19

News that an Austrian hospital using medical cannabis to treat patients with COVID-19 has yielded positive results is spurring investor interest in Incannex Healthcare (ASX: IHL), according to the Aus...
Incannex IHL ASX inflammatory lung conditions COPD asthma bronchitis in vivo

Incannex Healthcare study finds lead drug IHL-675A has ‘superior’ anti-inflammatory capabilities

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has received positive results from an additional in vivo study in assessing the anti-inflammatory capabilities of its l...
Incannex Healthcare IHL ASX quarter record sales therapeutic portfolio December 2020

Incannex Healthcare achieves another quarter of record sales, therapeutic portfolio advances

The December 2020 quarter heralded Incannex Healthcare’s (ASX: IHL) fifth consecutive period of record sales receipts, while it continued to advance its proprietary therapeutics for sleep apnoea, seps...
Incannex Healthcare IHL ASX first patients phase 2 obstructive sleep apnoea clinical trial

Incannex Healthcare recruits for IHL-42X obstructive sleep apnoea clinical trial

On a path to developing a suite of cannabinoid-based medicines aimed at remedying a range of debilitating conditions, pharmaceutical development company Incannex Healthcare (ASX: IHL) has recruited th...
Incannex Healthcare ASX IHL IHL-216A traumatic brain injury in vivo cannabidiol TBI

Pre-clinical research of Incannex Healthcare’s IHL-216A drug found it effective preventing traumatic brain injury

Incannex Healthcare (ASX: IHL) has revealed more positive in vivo research for its IHL-216A drug, this time regarding traumatic brain injury and has filed a patent application to cover this intellectu...
Incannex Healthcare ASX IHL Monash University psilocybin assisted psychotherapy anxiety disorder

Incannex Healthcare and Monash University to undertake ‘world first’ trial using psilocybin mushrooms to treat anxiety

Incannex Healthcare (ASX: IHL) has partnered with Monash University to undertake a “world first” clinical trial using psilocybin-assisted psychotherapy to treat generalised anxiety disorder. Accord...
Incannex Healthcare ASX IHL in vivo drug COVID-19 infection anti-inflammatory

Incannex Healthcare reveals positive in vivo results, will call Pre-IND meeting with FDA

Cannabinoid development company Incannex Healthcare (ASX: IHL) has unveiled the latest test results of its lead drug candidate IHL-675A, which show its anti-inflammatory potency make it an excellent c...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS